• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尼日利亚 HIV-1 感染者队列中的 HIV-1 耐药性和遗传多样性。

HIV-1 drug resistance and genetic diversity in a cohort of people with HIV-1 in Nigeria.

机构信息

Department of Biological Sciences, Faculty of Natural Sciences.

African Centre of Excellence for Genomics of Infectious Diseases (ACEGID), Redeemer's University, Ede, Osun State, Nigeria.

出版信息

AIDS. 2022 Jan 1;36(1):137-146. doi: 10.1097/QAD.0000000000003098.

DOI:10.1097/QAD.0000000000003098
PMID:34628443
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8654252/
Abstract

OBJECTIVE

This study was designed to provide information on the genetic diversity of HIV-1 and drug resistance mutations in Nigeria, as there is limited understanding of variants circulating in the country.

METHODS

We used an advanced next-generation sequencing platform, Primer ID, to: investigate the presence of high and low abundance drug resistance mutations; characterize preexisting Integrase Strand Transfer Inhibitor (INSTI) mutations in antiretroviral therapy (ART)-experienced but dolutegravir-naive individuals; detect recent HIV-1 infections and characterize subtype diversity from a cohort of people with HIV-1 (PWH).

RESULTS

HIV-1 subtype analysis revealed the predominance of CRF02_AG and subtype G in our study population. At detection sensitivity of 30% abundance, drug resistance mutations (DRMs) were identified in 3% of samples. At a sensitivity level of 10%, DRMs were identified in 27.3% of samples. We did not detect any major INSTI mutation associated with dolutegravir-resistance. Only one recent infection was detected in our study population.

CONCLUSION

Our study suggests that dolutegravir-containing antiretroviral regimens will be effective in Nigeria. Our study also further emphasizes the high genetic diversity of HIV-1 in Nigeria and that CRF02_AG and subtype G are the dominant circulating forms of HIV-1 in Nigeria. These two circulating forms of the virus are largely driving the epidemic in the country.

摘要

目的

本研究旨在提供尼日利亚 HIV-1 遗传多样性和耐药突变的信息,因为人们对该国流行的变异体了解有限。

方法

我们使用先进的下一代测序平台 Primer ID:调查高和低丰度耐药突变的存在;描述抗逆转录病毒治疗 (ART) 经验丰富但多拉韦林初治个体中预先存在的整合酶链转移抑制剂 (INSTI) 突变;从一组 HIV-1 患者 (PWH) 中检测近期 HIV-1 感染并描述亚型多样性。

结果

HIV-1 亚型分析显示,我们的研究人群中以 CRF02_AG 和亚型 G 为主。在 30%丰度的检测灵敏度下,3%的样本中发现耐药突变 (DRMs)。在灵敏度水平为 10%时,27.3%的样本中发现了 DRMs。我们没有发现任何与多替拉韦耐药相关的主要 INSTI 突变。我们的研究人群中仅检测到一例近期感染。

结论

我们的研究表明,含多替拉韦的抗逆转录病毒方案将在尼日利亚有效。我们的研究还进一步强调了尼日利亚 HIV-1 的遗传多样性很高,CRF02_AG 和亚型 G 是尼日利亚流行的 HIV-1 主要循环形式。这两种循环形式的病毒在很大程度上推动了该国的疫情。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d66/8654252/6fecdaaccc83/aids-36-137-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d66/8654252/c19b201fa14c/aids-36-137-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d66/8654252/76febcd424e6/aids-36-137-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d66/8654252/6fecdaaccc83/aids-36-137-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d66/8654252/c19b201fa14c/aids-36-137-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d66/8654252/76febcd424e6/aids-36-137-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6d66/8654252/6fecdaaccc83/aids-36-137-g003.jpg

相似文献

1
HIV-1 drug resistance and genetic diversity in a cohort of people with HIV-1 in Nigeria.尼日利亚 HIV-1 感染者队列中的 HIV-1 耐药性和遗传多样性。
AIDS. 2022 Jan 1;36(1):137-146. doi: 10.1097/QAD.0000000000003098.
2
Baseline integrase drug resistance mutations and conserved regions across HIV-1 clades in Cameroon: implications for transition to dolutegravir in resource-limited settings.喀麦隆 HIV-1 各亚型中整合酶耐药突变和保守区的基线情况:对资源有限环境中向多替拉韦转换的影响。
J Antimicrob Chemother. 2021 Apr 13;76(5):1277-1285. doi: 10.1093/jac/dkab004.
3
Prevalence of integrase strand transfer inhibitor resistance mutations in antiretroviral-naive HIV-1-infected individuals in Cameroon.喀麦隆抗逆转录病毒初治的 HIV-1 感染者中整合酶抑制剂耐药突变的流行情况。
J Antimicrob Chemother. 2021 Jan 1;76(1):124-129. doi: 10.1093/jac/dkaa383.
4
HIV-1 Integrase Diversity and Resistance-Associated Mutations and Polymorphisms Among Integrase Strand Transfer Inhibitor-Naive HIV-1 Patients from Cameroon.喀麦隆初治HIV-1患者中HIV-1整合酶的多样性、与耐药相关的突变及多态性
AIDS Res Hum Retroviruses. 2020 May;36(5):450-455. doi: 10.1089/AID.2019.0264. Epub 2020 Jan 13.
5
Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.印度西部初治和经治抗逆转录病毒治疗个体中整合酶链转移抑制剂相关耐药性的缺失
AIDS Res Hum Retroviruses. 2019 Jun;35(6):567-571. doi: 10.1089/AID.2018.0272. Epub 2019 Apr 8.
6
Short Communication: HIV-1 Drug Resistance Mutation Analyses of Cameroon-Derived Integrase Sequences.短讯:喀麦隆来源整合酶序列的 HIV-1 耐药突变分析。
AIDS Res Hum Retroviruses. 2021 Jan;37(1):54-56. doi: 10.1089/AID.2020.0022. Epub 2020 Aug 10.
7
Integrase Strand Transfer Inhibitor Resistance in Integrase Strand Transfer Inhibitor-Naive Persons.整合酶抑制剂耐药在整合酶抑制剂初治者中。
AIDS Res Hum Retroviruses. 2021 Oct;37(10):736-743. doi: 10.1089/AID.2020.0261. Epub 2021 Apr 15.
8
Pre-Treatment Integrase Inhibitor Resistance and Natural Polymorphisms among HIV-1 Subtype C Infected Patients in Ethiopia.埃塞俄比亚 HIV-1 型 C 亚型感染患者的治疗前整合酶抑制剂耐药性和自然多态性。
Viruses. 2022 Mar 30;14(4):729. doi: 10.3390/v14040729.
9
Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.整合酶抑制剂耐药突变的积累赋予了来自乌干达因拉替拉韦治疗失败的非 B 亚型 HIV-1 患者对多替拉韦的高水平耐药性。
J Antimicrob Chemother. 2020 Dec 1;75(12):3525-3533. doi: 10.1093/jac/dkaa355.
10
HIV-1 Genetic Diversity and Natural Polymorphisms of the Integrase Gene in Integrase Inhibitor-Naive Patients in Harare, Zimbabwe.津巴布韦哈拉雷地区初治整合酶抑制剂患者的 HIV-1 基因多样性及整合酶基因天然多态性。
AIDS Res Hum Retroviruses. 2021 Dec;37(12):954-961. doi: 10.1089/AID.2021.0084.

引用本文的文献

1
The Transformative Impact of the African Cohort Study (AFRICOS) Toward Reaching HIV 95-95-95 Goals in Sub-Saharan Africa.非洲队列研究(AFRICOS)对撒哈拉以南非洲地区实现艾滋病病毒“95-95-95”目标的变革性影响。
Am J Trop Med Hyg. 2024 Oct 29;112(1):45-55. doi: 10.4269/ajtmh.24-0249. Print 2025 Jan 8.
2
HIV-1 diversity and pre-treatment drug resistance in the era of integrase inhibitor among newly diagnosed ART-naïve adult patients in Luanda, Angola.安哥拉罗安达新诊断的未接受抗逆转录病毒治疗的成年患者中整合酶抑制剂时代的 HIV-1 多样性和治疗前耐药性。
Sci Rep. 2024 Jul 10;14(1):15893. doi: 10.1038/s41598-024-66905-1.
3
Immunological and molecular assessment of HIV-1 mutations for antiretroviral drug resistance in Saudi Arabia.
沙特阿拉伯抗逆转录病毒药物耐药性的 HIV-1 突变的免疫和分子评估。
PLoS One. 2024 Jun 26;19(6):e0304408. doi: 10.1371/journal.pone.0304408. eCollection 2024.
4
A unified classification system for HIV-1 5' long terminal repeats.HIV-1 5' 长末端重复序列的统一分类系统。
PLoS One. 2024 May 2;19(5):e0301809. doi: 10.1371/journal.pone.0301809. eCollection 2024.